Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?: A Pre-Specified Analysis From the ZEUS Trial

详细信息    查看全文

• 作者：Sara Ariotti ; MD^a ; ^b ; Marianna Adamo ; MD^b ; Francesco Costa ; MD^b ; Athanasios Patialiakas ; MD^c ; Carlo Briguori ; MD ; PhD^d ; Attila Thury ; MD ; PhD^e ; Salvatore Colangelo ; MD^f ; Gianluca Campo ; MD^g ; Matteo Tebaldi ; MD^g ; Imre Ungi ; MD ; PhD^e ; Stefano Tondi ; MD^h ; Marco Roffi ; MDⁱ ; Alberto Menozzi ; MD ; PhD^j ; Nicoletta de Cesare ; MD^k ; Roberto Garbo ; MD^f ; Emanuele Meliga ; MD^l ; Luca Testa ; MD ; PhD^m ; Henrique Mesquita Gabriel ; MDⁿ ; Marco Ferlini ; MD^o ; Pascal Vranckx ; MD ; PhD^p ; Marco Valgimigli ; MD ; PhD^a ; ^b ; ^{marco.valgimigli@insel.ch" class="auth_mail" title="E-mail the corresponding author} ; for the ZEUS Investigators
• 关键词：dual antiplatelet therapy ; high bleeding risk ; zotarolimus-eluting stent(s)
• 刊名：JACC: Cardiovascular Interventions
• 出版年：2016
• 出版时间：14 March 2016
• 年：2016
• 卷：9
• 期：5
• 页码：426-436
• 全文大小：972 K

文摘

This study sought to investigate the ischemic and bleeding outcomes of patients fulfilling high bleeding risk (HBR) criteria who were randomized to zotarolimus-eluting Endeavor Sprint stent (E-ZES) or bare-metal stent (BMS) implantation followed by an abbreviated dual antiplatelet therapy (DAPT) duration for stable or unstable coronary artery disease.

Background

DES instead of BMS use remains controversial in HBR patients, in whom long-term DAPT poses safety concerns.

Methods

The ZEUS (Zotarolimus-Eluting Endeavor Sprint Stent in Uncertain DES Candidates) is a multinational, randomized single-blinded trial that randomized among others, in a stratified manner, 828 patients fulfilling pre-defined clinical or biochemical HBR criteria—including advanced age, indication to oral anticoagulants or other pro-hemorrhagic medications, history of bleeding and known anemia—to receive E-ZES or BMS followed by a protocol-mandated 30-day DAPT regimen. The primary endpoint of the study was the 12-month major adverse cardiovascular event rate, consisting of death, myocardial infarction, or target vessel revascularization.

Results

Compared with patients without, those with 1 or more HBR criteria had worse outcomes, owing to higher ischemic and bleeding risks. Among HBR patients, major adverse cardiovascular events occurred in 22.6% of the E-ZES and 29% of the BMS patients (hazard ratio: 0.75; 95% confidence interval: 0.57 to 0.98; p = 0.033), driven by lower myocardial infarction (3.5% vs. 10.4%; p < 0.001) and target vessel revascularization (5.9% vs. 11.4%; p = 0.005) rates in the E-ZES arm. The composite of definite or probable stent thrombosis was significantly reduced in E-ZES recipients, whereas bleeding events did not differ between stent groups.

Conclusions

Among HBR patients with stable or unstable coronary artery disease, E-ZES implantation provides superior efficacy and safety as compared with conventional BMS. (Zotarolimus-Eluting Endeavor Sprint Stent in Uncertain DES Candidates [ZEUS]; NCT01385319)